Gilead Sciences (GILD, Financial) reported outcomes from the Phase 3 ASCENT-07 trial evaluating Trodelvy against chemotherapy for HR+/HER2-negative metastatic breast cancer following endocrine therapy. The trial did not reach its main goal of improving progression-free survival, as determined by independent review. Early results suggest that Trodelvy may offer a survival advantage over chemotherapy, although these findings are not yet mature. The trial will proceed to gather more data on overall survival. Trodelvy's safety profile aligned with previous studies, and no new concerns were identified.
Trodelvy is globally sanctioned as a Trop-2-directed antibody-drug conjugate, demonstrating significant survival benefits in specific metastatic breast cancer categories. It holds key recommendations per the National Comprehensive Cancer Network and significant ratings by the European Society for Medical Oncology. Gilead continues to expand Trodelvy's applications through ongoing research, including trials for early-stage TNBC and other cancers. It is important to note that Trodelvy's use in these contexts remains investigative, with safety and effectiveness yet to be established.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.